P53 protein expression as prognostic factor in human pancreatic cancer

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2779-2788

  Sato, Yoshitoshi ^a   Nio, Yoshinori ^a   Song, Mou Ming ^a   Sumi, Shoichiro ^a   Hirahara, Noriyuki ^a   Minari, Yoshimitsu ^a   Tamura, Katsuhiro ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

p53; Pancreatic cancer

Indexed keywords

BIOTIN; MONOCLONAL ANTIBODY; PROTEIN P53; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PANCREAS RESECTION; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADENOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUCINS; NEOPLASM METASTASIS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030755785     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Poston GJ, Gillespie J and Guillou PJ: Biology of pancreatic cancer. Gut 32: 800-812, 1991.
2. Almoguera C, Shibata D, Forrester K, Martin J, Peerucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554, 1988.
3. Grunewald K, Lyons J, Frohlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037-1041, 1989.
4. Tada M and Omata M: Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology 100: 233-238, 1991.
5. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T and Kanematsu T: Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 86: 1784-1788, 1991.
6. Song MM, Nio Y, Sato Y, Tamura K and Furuse K: Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatology 20: 27-35, 1996.
7. Finlay CA, Hinds PW and Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
8. Jenkins JR, Rudge K, Chumakov P and Currie GA: The cellular oncogene p53 can be activated by mutagenesis. Nature 317: 816-818, 1985.
9. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 cdk-interacting protein Cip 1 is a potent inhibitor of G1 cycline-dependent kinases. Cell 75: 805-816, 1993.
11. Lee CS, Rush M, Charalambous D and Rode J: Immunohisto-chemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis. J Gastroenterology and Hepatology 8: 465-469, 1993.
12. American Joint Committee on Cancer, TNM Committee of the International Union Against Cancer. Staging of Cancer from the Manual for Staging of Cancer, Fourth Edition.
13. Vojtesek B, Bartek J, Midgley CA and Lane DP. An immuno-chemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immonol Methods 151: 237-244, 1992.
14. Wilcock D and Lane DP: Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 349: 429-431, 1991.
15. Bartek J, Barkova J, Vojtesek B, et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.
16. Porter PL, Grown AM, Kramp SG and Coltera MD: Widespread p53 overexpression in human malignant tumors: an immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 140: 145-153, 1992.
17. Martin HM, Filipe MI, Morris RW, Lane DP and Silvestre F: p53 expression and prognosis in gastric carcinoma. Int. J Cancer 50: 859-862, 1992
18. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K and Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-845, 1991.
19. Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E and Alajmo E: p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 75: 2037-2044, 1995.
20. Motojima K, Furui J, Kohara N, Ito T and Kanematsu T: Expression of p53 protein in gastric carcinoma is not independently prognostic. Surgery 116: 890-895, 1994.
21. Zhang SY, Ruggeri B, Agarwal P, Sorling AF, Obara T, Ura H, Namiki M and Klein-Szanto AJP: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch Pathol Lab Med 118: 150-154, 1994.
22. Martinez J, Georgoff I, Martinez J and Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Gene and Development 5: 151-159, 1991.